Search results
Results From The WOW.Com Content Network
The maker of vaccines, including the mRNA vaccine for COVID-19, is amid a 90% stock price downturn. In fact, the share price is now only right around the same level as it was before the 2020 pandemic.
Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The biotech, renowned for its pioneering development of vaccines based on ...
If we assume Moderna only hits the low end of its 2025 revenue forecast, the stock trades at roughly 9 times forward sales. That's well above the 7.2 price-to-sales ratio for the biotech industry.
Moderna stock gained 14%, shooting up to $48.56 per share Tuesday afternoon. Vaccine-makers Novavax and CureVac similarly rose, soaring 15% and 10%, respectively, while Pfizer gained 2% and GSK ...
Year to date, Moderna stock has plunged over 60%, with a 52-week low-high of $35.8-$170.47, as per data from Benzinga Pro. ... Price Action: MRNA stock is down 1.04% at $41. ... "ACTIVE INVESTORS ...
Moderna held its annual R&D day this week. Moderna's (NASDAQ: MRNA) struggles may last a little longer than expected. The biotech company had seen both sales and its stock price plummet as demand ...
Moderna stock fell over 9% on Wednesday, forfeiting most of its gains from Tuesday's session during a volatile week for the stock seen after the first reported bird flu death in the US, which put ...
Moderna's (NASDAQ: MRNA) wild success in the COVID-19 vaccine market has worn off. The company's revenue, earnings, and stock price have been moving in the wrong direction for the past three years ...